Liraglutide addition to MDI aims to reduce HbA1c in overweight Type 2 Diabetes
Background
Type 2 Diabetes (T2D) management often progresses to Multiple Daily Insulin Injections (MDI) as a final therapeutic option, particularly for patients with inadequate glycemic control and weight gain. Despite MDI, many individuals struggle to achieve target HbA1c levels, highlighting a critical unmet need for adjunctive therapies. Glucagon-like peptide 1 (GLP-1) analogues, like liraglutide, have demonstrated efficacy in improving glycemic control and promoting weight loss in T2D patients on oral anti-diabetes therapy. However, their utility specifically when added to MDI regimens, a population typically facing more severe disease progression, remains underexplored in clinical trials. This study aims to bridge that knowledge gap.
Study Design
This is a planned 24-week randomized, placebo-controlled clinical trial involving 120 patients across 15 centers in Sweden. The study population comprises overweight and obese Type 2 Diabetes patients who are currently on Multiple Daily Insulin Injections (MDI) but exhibit inadequate glycemic control. Participants will be randomized to receive either liraglutide or a placebo in addition to their existing MDI regimen. The primary objective is to evaluate the reduction in HbA1c levels, comparing the liraglutide group against the placebo group. MDI is strictly defined as basal insulin combined with separate mealtime insulin injections, excluding premixed insulin regimens.
Results
This abstract describes a study protocol, therefore, no direct findings are presented. The core hypothesis is that adding liraglutide to an MDI regimen will significantly improve glycemic control in a challenging patient population. The study is designed to provide robust evidence on this crucial clinical question, which currently lacks dedicated trials. Researchers anticipate that liraglutide's known mechanisms, including glucose-dependent insulin secretion stimulation and glucagon suppression, will translate into a measurable reduction in HbA1c. While specific numerical outcomes are not yet available, the study's primary aim is clearly defined:
Why It Matters
If this planned trial demonstrates a significant reduction in HbA1c and potentially beneficial effects on weight, it could fundamentally alter the treatment paradigm for Type 2 Diabetes patients on Multiple Daily Insulin Injections (MDI). Integrating GLP-1 analogues like liraglutide into MDI protocols could offer a much-needed adjunctive therapy, improving glycemic outcomes and potentially mitigating weight gain often associated with intensive insulin therapy. This could lead to updated clinical guidelines, providing clinicians with a new strategy for patients who have exhausted other options. For individuals managing advanced T2D, this could mean better disease control, reduced complications, and an improved quality of life, moving beyond MDI as the "final" and often insufficient therapeutic step. The findings could inform future dosing and combination strategies for liraglutide in this specific, high-need population.